Peroxiredoxin 4 (PRDX4) is a member of the peroxiredoxin family of antioxidant enzymes. Previously, we reported that PRDX4 can restrain the initiation and progression of nonalcoholic steatohepatitis by reducing local and systemic reactive oxygen species (ROS) levels. Oxidative stress is recognized as a key factor in hepatocarcinogenesis, and a high ROS level has also been found in hepatocellular carcinoma (HCC). Here, our aim is to investigate roles of PRDX4 in the initiation and progression of HCC.
Results:
In this study, for hepatocarcinogenesis, wild-type (WT), PRDX4 knockout (PRDX4−/y), and human PRDX4 transgenic (hPRDX4+/+) mice were given a weekly intraperitoneal injection of diethylnitrosamine for 25 weeks. The HCC incidence was higher in PRDX4−/y mice than in WT or hPRDX4+/+ mice. Intrahepatic and circulating oxidative stress and inflammatory cell infiltration in the liver were obviously decreased in hPRDX4+/+ mice, compared with WT mice. Furthermore, in our cohort study, human HCC specimens with low expression of PRDX4 had higher ROS levels and a highly malignant phenotype, which was associated with a reduced overall survival, compared with those with high PRDX4 expression. However, in human HCC cell lines, PRDX4 knockdown led to a rapidly increased intracellular ROS level and suppressed cell proliferation, inducing cell death.
Innovation and Conclusion:
Our results clearly indicate that PRDX4 has an inhibitory effect in the initiation of HCC, but a dual (inhibitory or promoting) role in the progression of HCC, suggesting the potential utility of PRDX4 activators or inhibitors as therapy for different stages and phenotypes of HCC.
Get full access to this article
View all access options for this article.
References
1.
Afanas'evI. Reactive oxygen species signaling in cancer: comparison with aging. Aging Dis, 2: 219–230, 2011.
2.
Al DhaheriY, AttoubS, RamadanG, ArafatK, BajboujK, KaruvantevidaN, AbuQamarS, EidA, and IratniR. Carnosol induces ROS-mediated beclin1-independent autophagy and apoptosis in triple negative breast cancer. PLoS One, 9: e109630, 2014.
3.
AmstadP, CrawfordD, MuehlematterD, ZbindenI, LarssonR, and CeruttiP. Oxidants stress induces the proto-oncogenes c-fos and cinogenesis c-myc in mouse epidermal cells. Bull Cancer, 77: 501–502, 1990.
4.
AravalliRN, SteerCJ, and CressmanEN. Molecular mechanisms of hepatocellular carcinoma. Hepatology, 48: 2047–2063, 2008.
5.
BenharM, DalyotI, EngelbergD, and LevitzkiA. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol, 21: 6913–6926, 2001.
6.
BremerE, van DamG, KroesenBJ, de LeijL, and HelfrichW. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med, 12: 382–393, 2006.
7.
ByunJM, KimSS, KimKT, KangMS, JeongDH, LeeDS, JungEJ, KimYN, HanJ, SongIS, LeeKB, and SungMS. Overexpression of peroxiredoxin-3 and −5 is a potential biomarker for prognosis in endometrial cancer. Oncol Lett, 15: 5111–5118, 2018.
8.
CarewJS, KellyKR, and NawrockiST. Autophagy as a target for cancer therapy: new developments. Cancer Manag Res, 4: 357–365, 2012.
9.
ChangKP, YuJS, ChienKY, LeeCW, LiangY, LiaoCT, YenTC, LeeLY, HuangLL, LiuSC, ChangYS, and ChiLM. Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res, 10: 4935–4947, 2011.
10.
ChioIIC and TuvesonDA. ROS in cancer: the burning question. Trends Mol Med, 23: 411–429, 2017.
11.
Del CampoJA, GallegoP, and GrandeL. Role of inflammatory response in liver diseases: therapeutic strategies. World J Hepatol, 10: 1–7, 2018.
12.
DentonD, XuT, and KumarS. Autophagy as a pro-death pathway. Immunol Cell Biol, 93: 35–42, 2015.
13.
DingC, FanX, and WuG. Peroxiredoxin 1—an antioxidant enzyme in cancer. J Cell Mol Med, 21: 193–202, 2017.
14.
DingY, YamadaS, WangKY, ShimajiriS, GuoX, TanimotoA, MurataY, KitajimaS, WatanabeT, IzumiH, KohnoK, and SasaguriY. Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. Antioxid Redox Signal, 13: 1477–1490, 2010.
15.
FujiiJ, IkedaY, KurahashiT, and HommaT. Physiological and pathological views of peroxiredoxin 4. Free Radic Biol Med, 83: 373–379, 2015.
16.
GillJG, PiskounovaE, and MorrisonSJ. Cancer, oxidative stress, and metastasis. Cold Spring Harb Symp Quant Biol, 81: 163–175, 2016.
17.
GuoX, YamadaS, TanimotoA, DingY, WangKY, ShimajiriS, MurataY, KimuraS, TasakiT, NabeshimaA, WatanabeT, KohnoK, and SasaguriY. Overexpression of peroxiredoxin 4 attenuates atherosclerosis in apolipoprotein E knockout mice. Antioxid Redox Signal, 17: 1362–1375, 2012.
18.
HwangJA, SongJS, YuDY, KimHR, ParkHJ, ParkYS, KimWS, and ChoiCM. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma. Int J Clin Exp Pathol, 8: 6627–6635, 2015.
19.
IuchiY, OkadaF, TsunodaS, KibeN, ShirasawaN, IkawaM, OkabeM, IkedaY, and FujiiJ. Peroxiredoxin 4 knockout results in elevated spermatogenic cell death via oxidative stress. Biochem J, 419: 149–158, 2009.
20.
KawatsuY, KitadaS, UramotoH, ZhiL, TakedaT, KimuraT, HorieS, TanakaF, SasaguriY, IzumiH, KohnoK, and YamadaS. The combination of strong expression of ZNF143 and high MIB-1 labelling index independently predicts shorter disease-specific survival in lung adenocarcinoma. Br J Cancer, 110: 2583–2592, 2014.
21.
KimTH, SongJ, Alcantara LlagunoSR, MurnanE, LiyanarachchiS, PalanichamyK, YiJY, ViapianoMS, NakanoI, YoonSO, WuH, ParadaLF, and KwonCH. Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. PLoS One, 7: e42818, 2012.
22.
KitadaS, YamadaS, KumaA, OuchiS, TasakiT, NabeshimaA, NoguchiH, WangKY, ShimajiriS, NakanoR, IzumiH, KohnoK, MatsumotoT, and SasaguriY. Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer, 109: 472–481, 2013.
23.
KolajaKL and KlaunigJE. Vitamin E modulation of hepatic focal lesion growth in mice. Toxicol Appl Pharmacol, 143: 380–387, 1997.
24.
LalaouiN, LindqvistLM, SandowJJ, and EkertPG. The molecular relationships between apoptosis, autophagy and necroptosis. Semin Cell Dev Biol, 39: 63–69, 2015.
25.
LeeJS, ChuIS, MikaelyanA, CalvisiDF, HeoJ, ReddyJK, and ThorgeirssonSS. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet, 36: 1306–1311, 2004.
26.
LiZ, YamadaS, InenagaS, ImamuraT, WuY, WangKY, ShimajiriS, NakanoR, IzumiH, KohnoK, and SasaguriY. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer, 104: 1882–1889, 2011.
27.
LiouGY and StorzP. Reactive oxygen species in cancer. Free Radic Res, 44: 479–496, 2010.
28.
LuJ, TanM, and CaiQ. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett, 356: 156–164, 2015.
29.
MaedaS, KamataH, LuoJL, LeffertH, and KarinM. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell, 121: 977–990, 2005.
30.
MarxJ. .. Cancer research. Inflammation and cancer: the link grows stronger. Science, 306: 966–968, 2004.
31.
MatésJM, SeguraJA, AlonsoFJ, and MárquezJ. Oxidative stress in apoptosis and cancer: an update. Arch Toxicol, 86: 1649–1665, 2012.
32.
NabeshimaA, YamadaS, GuoX, TanimotoA, WangKY, ShimajiriS, KimuraS, TasakiT, NoguchiH, KitadaS, WatanabeT, FujiiJ, KohnoK, and SasaguriY. Peroxiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model. Antioxid Redox Signal, 19: 1983–1998, 2013.
33.
NauglerWE, SakuraiT, KimS, MaedaS, KimK, ElsharkawyAM, and KarinM. Gender disparity in liver cancer due to sex differences inMyD88-dependent IL-6 production. Science, 317: 121–124, 2007.
34.
NawataA, NoguchiH, MazakiY, KurahashiT, IzumiH, WangKY, GuoX, UramotoH, KohnoK, TaniguchiH, TanakaY, FujiiJ, SasaguriY, TanimotoA, NakayamaT, and YamadaS. Overexpression of peroxiredoxin 4 affects intestinal function in a dietary mouse model of nonalcoholic fatty liver disease. PLoS One, 11: e0152549, 2016.
35.
NeumannCA and FangQ. Are peroxiredoxins tumor suppressors?. Curr Opin Pharmacol, 7: 375–380, 2007.
36.
NeumannCA, KrauseDS, CarmanCV, DasS, DubeyDP, AbrahamJL, BronsonRT, FujiwaraY, OrkinSH, and Van EttenRA. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature, 424: 561–565, 2003.
37.
NicolussiA, D'InzeoS, CapalboC, GianniniG, and CoppaA. The role of peroxiredoxins in cancer. Mol Clin Oncol, 6: 139–153, 2017.
38.
PahlHL and BaeuerlePA. Oxygen and the control of gene expression. Bioessays, 16: 497–502, 1994.
39.
PalandeKK, BeekmanR, van der MeerenLE, BeverlooHB, ValkPJ, and TouwIP. The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia. PLoS ONE, 6: e16340, 2011.
40.
Poillet-PerezL, DespouyG, Delage-MourrouxR, and Boyer-GuittautM. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol, 4: 184–192, 2015.
41.
PrasadS, GuptaSC, PandeyMK, TyagiAK, and DebL. Oxidative stress and cancer: advances and challenges. Oxid Med Cell Longev, 2016: 5010423, 2016.
42.
QuanC, ChaEJ, LeeHL, HanKH, LeeKM, and KimWJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol, 175: 1512–1516, 2006.
43.
ReuterS, GuptaSC, ChaturvediMM, and AggarwalBB. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med, 49: 1603–1616, 2010.
44.
RolfsF, HuberM, GruberF, BöhmF, PfisterHJ, BochkovVN, TschachlerE, DummerR, HohlD, SchäferM, and WernerS. Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis. Cancer Res, 73: 3460–3469, 2013.
45.
Scherz-ShouvalR, ShvetsE, FassE, ShorerH, GilL, and ElazarZ. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J, 26: 1749–1760, 2007.
46.
Schulte-HermannR, Timmermann-TrosienerI, BarthelG, and BurschW. DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res, 50: 5127–5135, 1990.
47.
SeoMJ, LiuX, ChangM, and ParkJH. GATA-binding protein 1 is a novel transcription regulator of peroxiredoxin 5 in human breast cancer cells. Int J Oncol, 40: 655–664, 2012.
48.
SoiniY, KallioJP, HirvikoskiP, HelinH, Kellokumpu-LehtinenP, KangSW, TammelaTL, PeltoniemiM, MartikainenPM, and KinnulaVL. Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma. APMIS, 114: 329–337, 2006.
49.
SosaV, MolinéT, SomozaR, PaciucciR, KondohH, and LLeonartME. Oxidative stress and cancer: an overview. Ageing Res Rev, 12: 376–390, 2013.
50.
TakanoS, FujibayashiK, FujiokaN, UenoE, WakasaM, KawaiY, and KajinamiK. Circulating glutamate and taurine levels are associated with the generation of reactive oxygen species in paroxysmal atrial fibrillation. Dis Markers, 2016: 7650976, 2016.
51.
UmmanniR, BarretoF, VenzS, ScharfC, BarettC, MannspergerHA, BraseJC, KunerR, SchlommT, SauterG, SültmannH, KorfU, BokemeyerC, WaltherR, BrümmendorfTH, and BalabanovS. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res, 11: 2452–2466, 2012.
52.
VillanuevaA, Hernandez-GeaV, and LlovetJM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol, 10: 34–42, 2013.
53.
WangZ, LiZ, YeY, XieL, and LiW. Oxidative stress and liver cancer: etiology and therapeutic targets. Oxid Med Cell Longev, 2016: 7891574, 2016.
54.
YamadaS and GuoX. Peroxiredoxin 4 (PRDX4): its critical in vivo roles in animal models of metabolic syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease. Pathol Int, 68: 91–101, 2018.
55.
ZhangW, WanX, LiuZ, XiaoL, HuangH, and LiuX. The emerging role of oxidative stress in regulating autophagy: applications of cancer therapy. Cell Mol Biol (Noisy-le-Grand), 63: 67–76, 2017.
56.
ZhengN, LiuL, LiuWW, LiF, HayashiT, TashiroSI, OnoderaS, and IkejimaT. Crosstalk of ROS/RNS and autophagy in silibinin-induced apoptosis of MCF-7 human breast cancer cells in vitro. Acta Pharmacol Sin, 38: 277–289, 2017.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
